Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme

J Hosp Infect. 2008 Jan;68(1):73-82. doi: 10.1016/j.jhin.2007.10.016.

Abstract

From April 1996 to July 2004, an outbreak of metallo-beta-lactamase-positive (MBL) Pseudomonas aeruginosa occurred in the haematology ward at Nantes University Hospital in France. Fifty-nine patients were carriers of VIM-2-positive strains of whom 14 were infected (mostly urinary tract infections and pneumonia). Pulsed-field gel electrophoresis identified related isolates demonstrating resistance to all beta-lactams, aminoglycosides, fluoroquinolones, fosfomycin, rifampicin but not colistin. The bla(VIM-2) gene responsible for VIM-2 MBL was not plasmid-encoded but part of a novel type of class 1 integron. VIM-2-positive strains were mostly from urine samples and clinical data suggest that in the absence of therapeutic guidelines, piperacillin-tazobactam or aztreonam may be a reliable choice for treating infections with MBL-producing strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Base Sequence
  • Cross Infection / epidemiology
  • Cross Infection / microbiology*
  • Disease Outbreaks*
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • France / epidemiology
  • Hospitals, University
  • Humans
  • Integrons / genetics
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Phylogeny
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / epidemiology*
  • Pseudomonas Infections / genetics
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / genetics*
  • Pseudomonas aeruginosa / pathogenicity
  • beta-Lactamases / drug effects
  • beta-Lactamases / genetics*

Substances

  • beta-lactamase bla(vim-2)
  • beta-Lactamases

Associated data

  • GENBANK/AY507153